A: Rezon Bio offers biologics contract development and manufacturing services at competitive pricing while maintaining high European-quality standards. The cost structure reflects Rezon Bio’s biosimilar heritage: having developed and commercialized biosimilar products from gene to market, the team has optimized every stage of the manufacturing process for efficiency, speed, and yield, and applies those same principles to client programs. This includes proven expertise in cost of goods (COGS) optimization – identifying opportunities to reduce per-unit manufacturing costs without compromising product quality or regulatory compliance.
Two GMP-certified manufacturing sites in Poland combine Central European cost efficiency with the quality systems and regulatory standing required for FDA, EMA, and global market access. The result is a cost-competitive European CDMO option that delivers both upfront cost advantages and ongoing COGS improvements, without requiring clients to trade off quality, regulatory rigor, or manufacturing scale.
